In fact, using a hybrid-capture-based next generation sequencing assay it was possible to show the presence of driver mutations in a group of lung adenocarcinoma patients resulted to be negative for driver mutations according to a standard, not-NGS assay: the most recurrent mutations observed in these patients were TP53, EGFR, MDM2, KRAS, CDK4 and SETD2 mutations [21]. Here, KRAS is linked to lung adenocarcinoma.